What Is Rapport Therapeutics, Inc. (RAPP) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Rapport Therapeutics, Inc. at its current price of $39.93. The composite intrinsic value is estimated at $23.52 (-41.1% average return), with 5 models flagging overvaluation risk. Notably, First Chicago sees the most upside at +35.0% (fair value: $53.90), while Regime Cross is the most conservative at -94.2% ($2.33). The spread between these extremes — +129.2% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About RAPP?
8 of 13 models are currently active for RAPP. Of these, 2 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates RAPP's intrinsic value at $11.49, implying -71.2% downside from the current price. See which stocks rank higher →
How Does RAPP Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, RAPP ranks #249 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Rapport Therapeutics, Inc. operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating RAPP should weigh these sector-specific dynamics alongside our model-derived fair values.
Is RAPP a Value Trap?
CirclFi's Value Trap algorithm assigns RAPP a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Rapport Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Rapport Therapeutics, Inc.'s fundamental quality profile registers 4.7/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +129.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RAPP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RAPP's 8 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad